Solutions
Genfoquest supports early-stage discovery decisions through structured biological data analysis and traceable evidence outputs.
Core Solution Areas
Four focused solution tracks designed for teams that need clear, defensible choices in early-stage R&D.
Build a ranked target shortlist from multi-omic inputs, disease datasets, and tissue-level context. Each target is scored for disease linkage, selectivity risk, and translational fit.
Map target biology to practical binder options using epitope accessibility, expression profile, and mechanism requirements. The output is a modality-fit recommendation for antibody, nanobody, or related formats.
Run an early liability screen covering off-target expression, pathway cross-reactivity, and immunogenicity indicators. Findings are organized into a risk register before major experimental spend.
Package the analysis into a decision-ready dossier with key findings, open uncertainties, and recommended validation experiments. Documents are formatted for internal governance and partner review meetings.
Differentiation
Built for discovery teams that need biological rigor and decision speed, not generic analytics reports.
We combine complementary evidence sources instead of relying on one dataset or one score.
Models and outputs are interpreted through disease biology and translational relevance.
Every recommendation links back to evidence so teams can reproduce and review decisions.
Deliverables are structured for real milestone decisions, not just data processing output.
Use Cases
Support target and binder choices across complex immune biology.
Rank long candidate lists into actionable shortlists with clearer rationale.
Connect preclinical evidence with practical translational considerations.
Compare alternatives with consistent criteria for confident program choices.
Prepare structured evidence packages for internal and partner milestone discussions.
Next Step
If you need clearer early-stage choices across targets, binders, and risk, we can scope a focused collaboration.